Amplia has published its new Investor Newsletter today.
This edition includes a progress update from our ACCENT trial; an overview of the regulatory milestones that we’re working towards; and a Q&A with Amplia’s Director of Early Clinical Development, Charlotte Mulder.
Read the newsletter here.
